Motor function in Parkinson’s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa

Filip Bergquist¹,², Mats Ehrnebo³, Dag Nyholm⁴, Anders Johansson⁵, Fredrik Lundin⁶, Per Odin⁷, Per Svenningsson⁵, Nil Dizdar⁶, Elias Eriksson¹

1) Dept of Pharmacology, University of Gothenburg, 2) Neurology, Sahlgrenska University Hospital 3) Pharm Assist Sweden AB 4) Dept of Neuroscience, Uppsala University 5) Dept of Clinical Neurosciences, Karolinska Institutet 6) Dept of Biomedical and Clinical Sciences, Linköping University 7) Neurology, Dept of Clinical Sciences, Lund University

Background and objectives

LCIG is efficacious for treating motor fluctuations in Parkinson’s disease. Pharmacokinetic data indicate stable blood concentrations of levodopa, equivalent with those following LCIG, during treatment with DIZ101 and DIZ102.¹ The carbidopa blood concentration was however four times higher than with LCIG.¹ The objective of this study was to investigate if the efficacy of DIZ101 and DIZ102 is reduced compared to LCIG, indicating a negative effect of high carbidopa levels by inhibition of the conversion of levodopa to dopamine in the brain.

Method

DIZ101, DIZ102 and LCIG were compared in a randomized, 3-period crossover, open-label, multicenter trial where 18 patients with Parkinson’s disease completed all treatments. Formulations were infused for 16 hours. The effects of the treatments on motor symptoms were blindly assessed before and during infusions by repeated UPDRS, UdysRS and Treatment Response Scale (TRS) video rating of a subset of UPDRS III items and by concurrent passive accelerometry recordings with the Parkinson Kinetigraph (PKG) over 24h.

Results

Pharmacokinetic results have been published previously.¹ After 1.5h of infusion mean (SEM) UPDRS scores were reduced by 2.6 (0.98) points (17%) with DIZ101 (p=0.002), 3.34 (0.8) points (22%) with DIZ102 (p<0.001) and 2.5 (0.8) points (16%) with LCIG (p=0.002). Despite the about 4 times higher carbidopa concentrations with DIZ101 and DIZ102 as compared to LCIG there were no differences in motor examination ratings with respect to UPDRS (Fig. 1A) or UDysRS (Fig. 1B) between DIZ101, DIZ102 and LCIG at any of the assessed time points 1.5h, 5h, 6h, 7h and 14h. TRS ratings produced the same result (not shown). Similarly, the unfiltered PKG bradykinesia (BK) and dyskinesia (DK) scores (Fig. 2AB) improved rapidly after treatment onset and did not differ between treatments in any of the predefined periods of infusion (0-2h, 2-8h, 8-16h).

Conclusion

In 18 PD patients treated with DIZ101, DIZ102 and LCIG in a random crossover order, there was no observable trend for lower levodopa efficacy on motor symptoms, despite the previously reported higher carbidopa concentrations with DIZ101 and DIZ102 compared to LCIG. This indicates, in line with previous reports²,³ that high blood levels (up to approximately 800 ng/mL) of carbidopa do not reduce the CNS effect of levodopa.

Take home message

Subcutaneous (DIZ102) and intravenous (DIZ101) levodopa/carbidopa infusion are as efficacious as LCIG regarding motor function in advanced PD, despite much higher carbidopa blood concentrations.

References

1) Bergquist et al. Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology 2022;99:e965-e976.